In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136]

By icmt24

In a Phase III placebo-controlled trial of 815 patients with metastatic colorectal cancer who were randomized to receive combination bevacizumab therapy, bevacizumab produced a significantly better rate and duration of response compared with placebo [136].…